WO2003030965A3 - Artificial lymph node - Google Patents

Artificial lymph node Download PDF

Info

Publication number
WO2003030965A3
WO2003030965A3 PCT/DE2002/003465 DE0203465W WO03030965A3 WO 2003030965 A3 WO2003030965 A3 WO 2003030965A3 DE 0203465 W DE0203465 W DE 0203465W WO 03030965 A3 WO03030965 A3 WO 03030965A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymph node
module
artificial lymph
antigen
artificial
Prior art date
Application number
PCT/DE2002/003465
Other languages
German (de)
French (fr)
Other versions
WO2003030965A2 (en
Inventor
Martin Scholz
Original Assignee
Martin Scholz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin Scholz filed Critical Martin Scholz
Priority to DE10294532T priority Critical patent/DE10294532D2/en
Priority to AU2002349265A priority patent/AU2002349265A1/en
Publication of WO2003030965A2 publication Critical patent/WO2003030965A2/en
Publication of WO2003030965A3 publication Critical patent/WO2003030965A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/20—Pathogenic agents
    • A61M2202/203—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/20—Pathogenic agents
    • A61M2202/206—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to an artificial lymph node consisting of a module comprising an inlet and an outlet opening. In said module, a complex consisting of a cell that presents an antigen, MHC and an antigen is immobilised on a carrier. The inventive module can be used for patients or in clinical situations with a defective cellular immune response, e.g. against viral or bacterial infection pathogens or tumour antigens.
PCT/DE2002/003465 2001-09-27 2002-09-16 Artificial lymph node WO2003030965A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10294532T DE10294532D2 (en) 2001-09-27 2002-09-16 Artificial lymph node
AU2002349265A AU2002349265A1 (en) 2001-09-27 2002-09-16 Artificial lymph node

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10147639 2001-09-27
DE10147639.6 2001-09-27

Publications (2)

Publication Number Publication Date
WO2003030965A2 WO2003030965A2 (en) 2003-04-17
WO2003030965A3 true WO2003030965A3 (en) 2004-04-01

Family

ID=7700471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/003465 WO2003030965A2 (en) 2001-09-27 2002-09-16 Artificial lymph node

Country Status (3)

Country Link
AU (1) AU2002349265A1 (en)
DE (1) DE10294532D2 (en)
WO (1) WO2003030965A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE502004010393D1 (en) * 2004-03-04 2009-12-31 Leukocare Gmbh Leukocyte stimulation matrix
MXPA06013747A (en) * 2004-05-27 2007-03-15 Ceres Inc Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics.
JPWO2007069755A1 (en) * 2005-12-12 2009-05-28 独立行政法人理化学研究所 Efficient method for producing antigen-specific hybridomas using artificial lymph nodes
US9227005B2 (en) * 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1997003186A2 (en) * 1995-07-12 1997-01-30 Activated Cell Therapy, Inc. Method for in vitro proliferation of dentritic cells, composition containing the cells entrapped in a three-dimensional matrix and use for immunization
WO2000027999A2 (en) * 1998-11-12 2000-05-18 Cell Science Therapeutics, Inc. Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1997003186A2 (en) * 1995-07-12 1997-01-30 Activated Cell Therapy, Inc. Method for in vitro proliferation of dentritic cells, composition containing the cells entrapped in a three-dimensional matrix and use for immunization
WO2000027999A2 (en) * 1998-11-12 2000-05-18 Cell Science Therapeutics, Inc. Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANCHEREAU J & STEINMAN R M: "Dendritic cells and the control of immunity", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 392, no. 6673, 19 March 1998 (1998-03-19), pages 245 - 252, XP002134557, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
AU2002349265A1 (en) 2003-04-22
WO2003030965A2 (en) 2003-04-17
DE10294532D2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DE60238471D1 (en) Proteosome liposaccharide-VACCINE ADJUVANT
IL114444A0 (en) Multi-stage cascade boosting vaccine
NO972082L (en) Ostomioppsamlingssystem
HK1068810A1 (en) Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CY1106400T1 (en) COMPOSITION AND METHOD OF IMMUNOTHERAPY WITH CANCER ANTIGEN
DK1629088T3 (en) VARIABLES OF THE PROSTATASTIC CELL ANTIGEN (PSCA) AND ITS SEQUENCES
AU2002347404A1 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
TR199900656T2 (en) Inhibition of the 262 and 20S proteasome by danones.
CY1113064T1 (en) NUCLEAR ACID AND CORRESPONDING PROTEIN WITH TITLE 184P1E2 USEFUL IN CANCER TREATMENT AND DETECTION
WO2002008755A3 (en) Identifying antigen clusters for monitoring a global state of an immune system
WO2003030965A3 (en) Artificial lymph node
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
WO1997011667A3 (en) Therapeutic applications using horse serum
ATE445839T1 (en) LATENT TUBERCULOSIS DIAGNOSTIC ANTIGEN AND METHOD OF USE
WO2001077358A3 (en) Herpes viruses for immune modulation
BRPI0412913A (en) means for treating leishmaniasis infections
EP1211311A3 (en) Cord blood-derived activated lymphocytes and preparations containing said lymphocytes
WO2004049914A3 (en) Methods for reacting an antigen masking compound with red blood cells with high efficiency
EP2147682A3 (en) Vaccination with immuno-isolated cells producing an immunomodulator
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
WO2003076570A3 (en) Antigens and their use as diagnostics and vaccines against species of plasmodium
NO20054142L (en) In vitro diagnostic test for enteroviral infections
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
WO2003031470A3 (en) Dna-expression construct for treatment of infections with leishmaniasis
CY1108768T1 (en) NUCLEAR ACID AND CORRESPONDING PROTEIN 121P2A3 USEFUL FOR CANCER PROTECTION AND DETECTION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
REF Corresponds to

Ref document number: 10294532

Country of ref document: DE

Date of ref document: 20040826

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10294532

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP